Alopecia Areata: Beyond JAK Inhibitors, What Else Is in the Pipeline

JAK inhibitors are the most discussed alopecia areata treatment, but they're not the only approach advancing through the clinical pipeline. Several other immune-modulating strategies are in development, each targeting different aspects of the autoimmune attack on hair follicles. The expansion of options is welcome because JAK inhibitors don't work for everyone, carry meaningful side effects, and require chronic dosing.

Dupilumab, an IL-4/IL-13 receptor antagonist already approved for atopic dermatitis, has shown promise in case series for alopecia areata with concomitant atopy. The TH2 inflammatory pattern seen in many alopecia areata patients suggests dupilumab may be particularly effective in this subset. A formal Phase 2 trial reported in 2023 showed 32% of treated patients achieved SALT-50 (50% scalp coverage improvement) at 48 weeks, with safety profile similar to atopic dermatitis use.

Other approaches in development include IL-15 pathway inhibitors (targeting one of the key cytokines driving the alopecia areata immune response), CD8 T-cell depleting therapies, and topical formulations of established immunosuppressants for milder cases. The field is also revisiting older approaches like contact immunotherapy (DPCP/SADBE) with better-standardised protocols. For patients with refractory alopecia areata who haven't responded to JAK inhibitors, the pipeline now offers credible second-line options within reasonable time horizons.